Hepatitis B, Immune Response, Seroprevalence
Conditions
Brief summary
At present, children less than 15 y of age have been regarded as a key group for hepatitis B immunization in China. However, there is not yet special immunization strategy for population above 15 y of age. In this study, we investigated the seroprevalence of hepatitis B and immune response to HB vaccine among Chinese college students to uncover the need on universal mass vaccination or booster immunization only for students with HBV vaccination history against hepatitis B in Chinese college students to inform decision making.
Interventions
BIOLOGICALHBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)
Sponsors
Guangxi Center for Disease Control and Prevention
Hui Zhuang
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 30 Years
Healthy volunteers
Yes
Inclusion criteria
* Male and female freshmen in one college in Liuzhou city of Guangxi Zhuang Autonomous Region
Exclusion criteria
for vaccination study: * acute illness * immunocompromised conditions * renal insufficiency * pregnancy * allergic history to HB vaccine or yeast * positive for any of HBsAg, anti-HBs or anti-HBc
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti-HBs immune response in participants negative for HB sAg, anti-HBs and anti-HBc | Anti-HBs was assayed at Month 7 |
Secondary
| Measure | Time frame |
|---|---|
| Seroprevalence for HBsAg, anti-HBs and anti-HBc in Chinese college students | seroprevalence at baseline |
| Anti-HBs immune response in participants negative for HBsAg, anti-HBs and anti-HBc | Anti-HBs immune response at Month 1 |
Countries
China
Outcome results
None listed